Industry News
Biotechnology Industry News
Roche has reported another phase 3…
Roche has reported another phase 3 win for its oral selective estrogen receptor degrader. Success at a planned interim analysis positions giredestrant for use in the adjuvant setting, setting the Swiss drugmaker up to target
When Tim Hunt was invited to a…
When Tim Hunt was invited to a meeting with Robert F. Kennedy Jr. in early March, the Department of Health and Human Services secretary had only been sworn in a few weeks earlier.
Single-use technologies (SUT) are…
Single-use technologies (SUT) are well-suited for modular production environments and represent a valuable solution in today’s ever-evolving biologics development landscape.
Genmab has shed another…
Genmab has shed another antibody-drug conjugate from its April 2024 acquisition of ProfoundBio. The Danish pharma has dropped development of GEN1160, a company spokesperson confirmed to Fierce Biotech, halting a phase 1/2 trial of the
After laying off most of its staff…
After laying off most of its staff and partnering away its phase 3 cancer asset earlier this year, precision oncology outfit Repare Therapeutics has agreed to be acquired by nonprofit biotech XenoTherapeutics.
Bayer has built a home for Chinese…
Bayer has built a home for Chinese biopharma companies. Located in Beijing, the Bayer E-Town Open Innovation Center will incubate local biotechs starting with Suzhou Puhe BioPharma and Beijing Youngen Technology.
At the center of the acquisition…
At the center of the acquisition is Halda’s “hold and kill” bifunctional small molecule platform and a lead candidate in prostate cancer.
Cytokinetics may be counting down…
Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficatem. But for a biotech planning to commercialize its first drug—and without Big Pharma backing—the company's CEO Robert
Nxera Pharma has outlined plans to…
Nxera Pharma has outlined plans to lay off 15% of its staff and prioritize its pipeline as part of a push to clear its path to profitability.
Nuvalent has reported phase 1/2…
Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.
A San Diego biotech has set out to…
A San Diego biotech has set out to solve the formula for best-in-class antibody-drug conjugates, raising $120 million with support from Big Pharma Merck & Co. to fuel its efforts.
The biotech will use the funds to…
The biotech will use the funds to extend its clinical ambitions for its pipeline of DNA-damage-response-inhibiting cancer prospects.
After touting an impressive 1…
After touting an impressive 1 billion-euro-plus fundraising haul back in March, European venture capital firm Sofinnova Partners is back in the spotlight with the close of another flagship fund.
After already halving its…
After already halving its workforce twice since 2022, Sensei Therapeutics is forging ahead with another deep round of cuts.
Merck & Co. is spending $9.2…
Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year.
Bristol Myers Squibb and Johnson…
Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.
Applied Therapeutics’ lack of…
Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question whether the biotech will ever be able to get the drug to market.
Neuro biotech Ovid Therapeutics’…
Neuro biotech Ovid Therapeutics' C-suite is metamorphosing, with co-founder and longtime CEO Jeremy Levin, Ph.D., set to give up the reins. Levin will step down Jan. 1 to make room for Meg Alexander, who will become Ovid’s
European life sciences investor…
European life sciences investor Medicxi has raised 500 million euros (about $581.6 million) to go directly toward innovative biotechs.
Signed, sealed and delivered,…
Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to swoop in and snatch the